Sign Out
Pregnancy Category B: Teratogenic Effects: Studies to assess the effects of zolpidem on human reproduction and development have not been conducted.
Nonteratogenic Effects: Studies to assess the effects on children whose mother took zolpidem during pregnancy have not been conducted.
However, children born of mothers taking sedative/hypnotic drugs may be at some risk for withdrawal symptoms from the drug during the postnatal period. In addition, neonatal flaccidity has been reported in infants born of mothers who received sedative/hypnotic drugs during pregnancy.
Nursing Mothers: Studies in lactating mothers indicate that the half-life of zolpidem is similar to that in young normal volunteers (2.6±0.3 hr). Between 0.004 and 0.019% of the total administered dose is excreted into milk, but the effect of zolpidem on the infant is unknown.
The use of zolpidem tartrate in nursing mothers is not recommended.
